AbilityPharma, member of CATALONIA.HEALTH, announces a strategic collaboration with AGC Pharma Chemicals, a company specialized and dedicated to the International Contract Development and Manufacturing Organization (CDMO).
This collaboration consists in the manufacture of an active pharmaceutical ingredient (API) for the new oral treatment ABTL081 for pancreatic cancer. A treatment that is currently in international Phase 2b clinical trials. The collaboration with AGC Pharma Chemicals will allow progress in the implementation of this innovative therapy and take it from the laboratory to patients from all over the world.
“We are very pleased to begin this collaboration in the production of our drug with AGC, which for its quality, technical team and proximity we have chosen in a competitive process with five global companies,” says Carles Domènech, CEO and co-founder of AbilityPharma.
Akihiro Kadokura, CEO of AGC Pharma Chemicals, states: “The alliance with AbilityPharma for the production of this active pharmaceutical principle to fight pancreatic cancer, reaffirms and consolidates our commitment to improve people’s lives through the development and manufacture of API’s in Spain and globally. And always maintaining high standards of quality and sustainability. A clear example of this commitment is the investment in the new 7,500 square meter plant in Malgrat de Mar (Barcelona).”
Related news:
Comments